Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol

Basit Öğe Kaydı
dc.contributor.authorAfşar, Barış
dc.contributor.authorAğca, Erhan
dc.contributor.authorTürk, Süleyman
dc.date.accessioned2020-03-26T19:01:29Z
dc.date.available2020-03-26T19:01:29Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThe erythropoiesis-stimulating agent (ESA) hyporesponsiveness index (EHRI) calculated as the weekly dose of EPO divided by weight (kg) divided by hemoglobin level (g/dL) has been considered useful to assess ESA resistance. Recent evidence suggests that active vitamin D, cinacalcet, and paricalcitol use may be related with lower ESA resistance. We conducted this observational cross-sectional study to investigate ESA resistance calculated by the EHRI among patients using calcitriol, cinacalcet, and paricalcitol. Participants underwent a medical history taken, physical examination, measurement of biochemical analysis, calculation of dialysis adequacy, and EHRI. Sixty-five patients did not receive any treatment regarding vitamin D, paricalcitol, and cinacalcet (group 1), 41 were taking only vitamin D (group 2), 50 were taking only paricalcitol (group 3), 19 were taking only cinacalcet (group 4), and 21 were taking paricalcitol+cinacalcet (group 5). The EHRI values for groups 1, 2, 3, 4, and 5 were 11.36 +/- 8.72, 11.58 +/- 5.72, 8.29 +/- 5.54, 9.49 +/- 4.61, and 8.91 +/- 4.44 respectively (P=.034). Post hoc analysis showed that the EHRI differed between group 1 and group 3 (P=.017) and between group 2 and group 3 (P=.006). In linear regression analysis, use of paricalcitol was independently associated with EHRI. In conclusion, paricalcitol use was associated with lower EHRI levels as a measure of ESA resistance.en_US
dc.identifier.doi10.1002/jcph.556en_US
dc.identifier.endpage1285en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.issue11en_US
dc.identifier.pmid26032009en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1280en_US
dc.identifier.urihttps://dx.doi.org/10.1002/jcph.556
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31952
dc.identifier.volume55en_US
dc.identifier.wosWOS:000362376200011en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEY-BLACKWELLen_US
dc.relation.ispartofJOURNAL OF CLINICAL PHARMACOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectanemiaen_US
dc.subjectcinacalceten_US
dc.subjecterythropoietinen_US
dc.subjecthemodialysisen_US
dc.subjectparicalcitolen_US
dc.subjectvitamin Den_US
dc.titleComparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitolen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu